Golden Ten Data on May 9, Tianyancha App shows that recently, Hongji Biotechnology (Shanghai) Co., Ltd. has undergone industrial and commercial changes, adding Moutai Science and Technology Innovation (Beijing) Investment Fund Partnership (Limited Partnership) and CICC Qide New Medical (Guangzhou) Venture Capital Partnership (Limited Partnership) under CICC Capital as shareholders, the registered capital has increased from about 62.22 million RMB coins to about 72.8 million RMB coins, and longing key personnel have changed.

As of the close, the Shanghai Index falls 0.61%, the Shenzhen Component Index falls 1.35%, and the ChiNext Index falls 1.45%. On the disk, the precious metals zone was active, and gold in the west pumped and stopped; The concept of synthetic biology is active against the trend, with 20% of Ruifeng High Materials pump stopped, and long stocks such as Rhine Biotech pump stopped. In addition, coal, agriculture, animal husbandry and fishery, electricity, immunotherapy, pork concepts and other zone pump are among the top ; Real estate, games, cultural media, insurance, AI corpus, ChatGPT concept and other zone fall are among the top . More than 900 stocks in the two cities pumped.

On May 6, some investors asked whether the company's synthetic biology cooperation with Jiangnan University has achieved results? Rhine Biotech said on the interactive platform that the company and Jiangnan University focused on the R&D and industrialization of microbial synthesis technology of natural sweeteners such as mogrosides, and as of the end of 2023, the two sides have completed the first phase of the research goal of mogroside synthetic biology and the development plan of synthetic biotechnology of some high value-added ingredients of steviol glycosides as planned.

Golden Ten Data on May 6, the three major indexes opened higher today, as of the close, the Shanghai index pumped 1.16%, the Shenzhen Component Index pumped 2%, and the ChiNext index pumped 1.98%. On the disk, the chemical zone set off a pump stoppage, 20% of United Chemical and Qicai Chemical pump stopped, and Sanxiang New Materials, Poly United and other long stocks pump stopped. The pharmaceutical zone was active, with Zhaoyan New Drug, Tongce Medical, and Azure Biotech pumping and stopping. In addition, chemical fiber, chemical fertilizer, transportation equipment, public utilities, food and beverage, CRO, titanium dioxide concepts and other zone pump ranked first, and tourism hotels, education, smart government affairs, state-owned assets cloud concepts and other zone fall ranked first. More than 4,500 stocks in the two cities pumped.

Golden Finance reported that stablecoin issuance Tether has invested $200 million in biotech company Blackrock Neurotech. The investment was made through Tether's newly formed venture capital arm, Tether Evo. With this investment, Tether is now the longest shareholder of Blackrock Neurotech. Tether added that the investment will help Blackrock Neurotech fund the commercialisation and roll-out of its medical solutions and support its R&D efforts.

Golden ten data on April 29, Rhine Biotech recently accepted the agency survey said that it is now the end of April, raw material planting has basically entered the end, from the current grasp of the raw material planting situation, it is expected that this year's stevia extract and monk fruit extract product prices will be an upward trend, especially monk fruit extract, this year raw material prices are expected to gradually repair to the equilibrium price, and then drive the price of downstream products part of the pump.

The company announced in the evening that it has recently obtained the "Medical Device Registration Certificate (In Vitro Diagnostic Reagent)" for the soluble growth stimulating expression gene 2 protein detection kit (chemiluminescent immunoassay) issued by the Zhejiang Provincial Drug Administration.

1. AMD Introduces First Desktop AI Processor 2. Volkswagen has partnered with Cerence to integrate intelligent automotive-grade ChatGPT 3. The Apple Vision Pro will be available in the U.S. on February 2 with a starting price of $3499 4. Nvidia unveils new chips, announcing a leading position in the AI PC track 5. Microsoft launches AI Odyssey program to train 100,000 Indian developers in AI technology 6. Sony CRV Motor has reached a partnership with Microsoft that will enable Azure OpenAI Service to develop conversational personal assistants 7. Nvidia will cooperate with miHoYo, Tencent, NetEase and other game companies in the AI digital human business 8. Biotech company Amgen will build AI models to analyze human datasets

Nvidia said biotech company Amgen will build AI models for analyzing one of the world's largest human datasets, which will be trained on Nvidia's DGX Superpod, a full data center platform, as reported by Kim Shi on January 9.

According to the National Business Daily, recently, Rito Biotech completed a B2 round of financing of over 100 million yuan, led by Guoke Investment and well-known domestic funds, with Shenzhen Investment Holding Capital participating in the investment, and Dianshi Capital serving as the exclusive financial advisor. This round of financing will be mainly used for the production, commercialization and R&D iteration of core products. RETO is a developer of artificial intelligence medical equipment, the company is mainly engaged in providing human body full specimens, full process, fully automated, fully intelligent inspection products, and has developed a new generation of DeepCell based on artificial intelligence.

On December 15, Hotgen Biotech announced that the company recently established the "X-Gen AI New Drug Discovery and Design Research Center", which is expected to promote the application of artificial intelligence technology in the field of drug research and development and accelerate the process of new drug discovery and design.

PANews reported on October 31 that a16z plans to raise about $3.4 billion for its next core fund, which will invest in early-stage and seed-stage companies, according to Axios. The funding will be launched around the end of the year and is expected to close in the first half of 2024. In addition, A16Z also plans to raise funds for new growth funds in 2025, with a focus on investing in the cryptocurrency and biotech sectors.

Odaily Planet Daily reported that VitaDAO, a DeSci (decentralized science) project invested by pharmaceutical giant Pfizer, recently spun off a biotechnology company, Matrix Biosciences. Matrix Biosciences, a biotech company led by Vera Gorbunova, an anti-aging researcher at the University of Rochester, has an initial funding of $300,000 for the project, with more funding to be available in early 2024. The company aims to conduct research on the longevity and cancer-fighting properties of naked mole rats, and to study whether compounds found in naked mole rats could extend human lifespan. (blockworks)

VitaDAO Founds Biotech Firm to Advance Longevity Research, Develop Treatments for Cancer and Age-related Diseases VitaDAO, a decentralized autonomous organization (DAO), has launched Matrix Biosciences, a biotech company focused on advancing longevity research. Matrix Biosciences, majority-owned by VitaDAO, will operate as a centralized entity and work on developing treatments for cancer and age-related diseases using research on the naked mole-rat. The company aims to demonstrate the compatibility of blockchain technology with the biotech industry and is actively collaborating with regulators to ensure compliance.

PANews reported on October 9 that according to Decrypt, VitaDAO, a decentralized autonomous organization that aims to fund longevity research projects, has cooperated with famous biologist Vera Gorbunova to establish Matrix Biosciences, a biotechnology company that studies longevity. The company’s majority shareholder is VitaDAO, but due to the strict legal environment in the medical and healthcare fields, the company itself will still operate as a traditional company. VitaDAO will initially provide $300,000 in funding to Matrix Biosciences. The joint venture will then receive additional capital through its IP-NFT segmentation model. VitaDAO core member Eleanor Davies said Matrix Biosciences will study the anti-cancer, anti-pain and life-extending properties of a special substance rich in high molecular weight hyaluronic acid (HMW-HA) secreted by naked mole rats. It was reported in January this year that VitaDAO, a longevity research organization, completed US$4.1 million in financing, with Pfizer’s venture capital firm participating in the investment. Related reading: Can VitaDAO, which received investment from Pfizer, start a new narrative of decentralized science?

Golden Finance reports that VitaDAO, a community organization that funds and promotes early longevity research, announced that it has partnered with world-renowned biologist Vera Gorbunova to establish Matrix Biosciences. Gorbunova, a professor at the University of Rochester, is credited with discovering the anti-cancer properties of naked mole rats. Todd White, a core member of VitaDAO, said the idea behind the new company is to “bring the research within the DAO back into the real world” rather than keeping it on-chain. Matrix Biosciences will operate centrally like a traditional company.

According to a report by Webmaster Home on September 11, Baitu Biotech’s AIGP protein design platform released the first batch of user recruitment information for internal testing, limited to 50 users. This platform is a generative protein design platform launched based on Baitu Biotech's life science Foundation Model-xTrimo, which can support the generation and optimization of multiple types of proteins. The AIGP protein design platform does not require local deployment and can be used online instantly, and user data will be strictly encrypted and protected.